New Upstate Research Strategic Plan Learn More

Dr. Tamara Jamaspishvili recognized nationally for work developing an AI-based diagnostic tool, named 2022 Young Investigator

Search Research Website

Dr. Tamara Jamaspishvili recognized nationally for work developing an AI-based diagnostic tool, named 2022 Young Investigator

Tamara Jamaspishvili, MD/PhD has been named a 2022 James Coulter-PCF Young Investigator by the Prostate Cancer Foundation (PCF). Jamasphishvili is an assistant professor of Pathology at SUNY Upstate, and the director of the SUNY Upstate Pathology Research Core (SUNY SPORE). 

Dr. Tamara Jamaspishvili named the 2022 James Coulter-PCF Young Investigator by the Prostate Cancer Foundation.


Jamaspishvili is being recognized for her work developing artificial intelligence (AI)-based digital pathology method to help assess risk, treatment responses, and outcomes for prostate cancer patients. Her project could help guide physicians in the treatment management of patients with high-risk, advanced prostate cancer. This could also serve as a cost-efficient screening method in low-to-middle-income countries where genomic testing is still expensive and challenging.
“Along with the adoption of digital pathology in clinical practice, the approach to cancer research has dramatically changed,” says Jamaspishvili. “Merging of conventional pathology, genomics, oncology, computer and data science gives tremendous promise to advance personalized medicine and improve the quality of life of the patients by discovering new models of disease risk stratification and treatment management options.” Jamaspishvili’s research on tissue-based biomarkers using machine learning in prostate cancer showed the increased benefit of merging these disciplines for improved patients’ prognoses and outcomes.
Jamaspishvili highlights the need for biomarker research to advance precision medicine. “Developing bias-free, objective, quantitative approaches in pathology practices is a prerequisite for precision medicine and biomarker-guided clinical trials,” she explains. Jamaspishvili and her team plan to assess three crucial tumor suppressor genes PTEN, p53 and Rb1, which are known to be found in patients with more aggressive diseases and who are unlikely to respond to hormone therapy. They hope by examining scanned prostate cancer tissue, they can begin to unravel complex cellular and molecular relationships predicting disease progression, duration and response to hormonal treatment, and the development of hormone-resistant prostate cancer.
“As a junior faculty member in the SUNY Upstate Pathology department,” says Jamaspishvili, “it is a privilege to have this recognition for my ongoing prostate cancer research.”
PCF Young Investigator Awards are intended to identify a cohort of future research leaders who will keep the field of prostate cancer research vibrant with new ideas and offer career and project support for early-career physicians and scientists who are committed to advancing the prostate cancer field. Thirty-four PCF Young Investigator Awards totaling $7.2 million were granted to the promising next generation of cancer researchers.

Go to top